IP Library › Granted Patent US 12,295,994
Granted Patent B2
US 12,295,994 · App. 17/937,165 · Granted May 13, 2025

Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Inventors: Toni Weinschenk (Tuebingen, DE); Jens Fritsche (Tuebingen, DE); Harpreet Singh (Tuebingen, DE); Andrea Mahr (Tuebingen, DE); Martina Ott (Tuebingen, DE); Claudia Wagner (Tuebingen, DE); Oliver Schoor (Tuebingen, DE)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH
A61K39/0011A61K35/17A61K39/001174A61K39/001193A61K39/4611A61K39/4644C07K14/4748C07K14/70539C07K16/18C12N5/0636C12N15/115A61K38/00C07K7/00C07K2319/00C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,295,994
App. No.
17/937,165
Granted
May 13, 2025
Kind
B2
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims (19)

1. An isolated peptide consisting of the amino acid sequence TLDGAAVNQV (SEQ ID NO: 22) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

4. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , wherein the peptide is in the form of a chloride salt.

6. The composition of claim 4 , wherein the peptide is in the form of an acetate salt.

7. The composition of claim 4 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide)(PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-7.

10. The composition of claim 7 , wherein the adjuvant is IL-12.

11. The composition of claim 7 , wherein the adjuvant is IL-15.

12. The composition of claim 7 , wherein the adjuvant is IL-21.

13. The peptide in the form of a pharmaceutically acceptable salt of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

14. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

15. The composition of claim 7 , wherein the adjuvant is IL-1.

16. The composition of claim 7 , wherein the adjuvant is IL-4.

17. The composition of claim 7 , wherein the adjuvant is IL-13.

18. The composition of claim 7 , wherein the adjuvant is IL-23.

19. An isolated peptide consisting of the amino acid sequence TLDGAAVNQV (SEQ ID NO: 22) in the form of a salt.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: WEINSCHENK, TONI; FRITSCHE, JENS; SINGH, HARPREET; MAHR, ANDREA; OTT, MARTINA; WAGNER, CLAUDIA; SCHOOR, OLIVER
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 061316/0204 →
Priority Claims (1)
GB 1504502 · Mar 17, 2015 · national
Continuity (11)
Continuation 17327190 · May 21, 2021
Continuation 17229556 · Apr 13, 2021
Continuation 16911069 · Jun 24, 2020
Continuation 16851627 · Apr 17, 2020
Continuation 16748350 · Jan 21, 2020
Continuation 16563151 · Sep 6, 2019
Continuation 16409393 · May 10, 2019
Continuation 15869471 · Jan 12, 2018
Continuation 15073528 · Mar 17, 2016
Provisional Application 62134253 · Mar 17, 2015
Related Publication 20230065320A1 · Mar 2, 2023
References Cited (86)
US 8080634B2 · Singh et al. · 2011 [cited by applicant]
US 8623611B2 · Pierce et al. · 2014 [cited by applicant]
US 8669230B2 · Singh et al. · 2014 [cited by applicant]
US 8961985B2 · Weinschenk et al. · 2015 [cited by applicant]
US 9101585B2 · Fritsche et al. · 2015 [cited by applicant]
US 9175040B2 · Weinschenk et al. · 2015 [cited by applicant]
US 9511128B2 · Singh et al. · 2016 [cited by applicant]
US 9717774B2 · Fritsche et al. · 2017 [cited by applicant]
US 9895415B2 · Fritsche et al. · 2018 [cited by applicant]
US 9943579B2 · Weinschenk et al. · 2018 [cited by applicant]
US 9950048B2 · Singh et al. · 2018 [cited by applicant]
US 9993523B2 · Fritsche et al. · 2018 [cited by applicant]
US 9993540B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10064913B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10076560B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10357551B2 · Weinschenk et al. · 2019 [cited by applicant]
US 10449239B1 · Weinschenk et al. · 2019 [cited by applicant]
US 10561718B2 · Weinschenk et al. · 2020 [cited by applicant]
US 10576135B2 · Weinschenk et al. · 2020 [cited by applicant]
US 10668138B1 · Weinschenk et al. · 2020 [cited by applicant]
US 10729755B1 · Weinschenk et al. · 2020 [cited by applicant]
US 10792350B2 · Weinschenk et al. · 2020 [cited by applicant]
US 10898561B2 · Weinschenk et al. · 2021 [cited by applicant]
US 11007257B2 · Weinschenk et al. · 2021 [cited by applicant]
US 11007258B2 · Weinschenk et al. · 2021 [cited by applicant]
US 11116826B2 · Weinschenk et al. · 2021 [cited by applicant]
US 20040208881A1 · Burgeson et al. · 2004 [cited by applicant]
US 20090274714A1 · Singh et al. · 2009 [cited by applicant]
US 20140001546A1 · Bode et al. · 2014 [cited by applicant]
US 20140065620A1 · Perez et al. · 2014 [cited by applicant]
US 20170165335A1 · Weinschenk et al. · 2017 [cited by applicant]
US 20170304399A1 · Fritsche et al. · 2017 [cited by applicant]
US 20170319675A1 · Weinschenk et al. · 2017 [cited by applicant]
US 20180125929A1 · Fritsche et al. · 2018 [cited by applicant]
US 20180207251A1 · Weinschenk et al. · 2018 [cited by applicant]
US 20190076476A1 · Weinschenk et al. · 2019 [cited by applicant]
US 20210322527A1 · Weinschenk et al. · 2021 [cited by applicant]
US 20230065320A1 · Weinschenk et al. · 2023 [cited by applicant]
US 20230094790A1 · Weinschenk et al. · 2023 [cited by applicant]
US 20230241111A1 · Weinschenk et al. · 2023 [cited by applicant]
CL 2017002346A1 · 2018 [cited by applicant]
CL 201802427A1 · 2018 [cited by applicant]
CL 2021000623A1 · 2021 [cited by applicant]
CL 2021000624A1 · 2021 [cited by applicant]
EP 1760089A1 · 2007 [cited by applicant]
EP 3270952A1 · 2018 [cited by applicant]
JP 2003321494A · 2003 [cited by applicant]
JP 2010534464A · 2010 [cited by applicant]
WO 9511972A1 · 1995 [cited by applicant]
WO 0154712A1 · 2001 [cited by applicant]
WO 0240941A1 · 2002 [cited by applicant]
WO 03001032A2 · 2003 [cited by applicant]
WO 03010327A2 · 2003 [cited by applicant]
WO 2004030615A2 · 2004 [cited by applicant]
WO 2004050858A2 · 2004 [cited by applicant]
WO 2009015842A2 · 2009 [cited by applicant]
WO 2010037514A2 · 2010 [cited by applicant]
WO 2010047938A2 · 2010 [cited by applicant]
WO 2011113819A2 · 2011 [cited by applicant]
WO 2015018805A1 · 2015 [cited by applicant]
WO 2016146751A1 · 2016 [cited by applicant]
Berge et al. (J. Pharm. Sci. Jan. 1977; 66 (1): 1-19). [cited by examiner]
Paulekuhn et al. (J. Med. Chem. Dec. 27, 2007; 50 (26): 6665-72). [cited by examiner]
Sikora et al. (Pharmaceuticals (Basel). Dec. 2020; 13 (12): 442; pp. 1-29). [cited by examiner]
He et al. (Life Sci. 1999; 65 (4): 355-68). [cited by examiner]
Stevens et al. (Eur. J. Immunol. Apr. 1998; 28 (4): 1272-9). [cited by examiner]
Bilich et al. (Blood. Feb. 7, 2019; 133 (6): 550-565). [cited by examiner]
Olson et al. (Curr. Opin. Immunol. Oct. 2023; 84: 102356; pp. 1-9). [cited by examiner]
Pastuszka et al., “Flipping the Switch on Clathrin-Mediated Endocytosis using Thermally Responsive Protein Microdomains.” Advanced Functional Materials 24 (2014) 5340-5347. [cited by applicant]
Khotz et al., “Mapping two functional. domains of clathrin light chains with monoclonal antibodies.” The Journal of Cell Biology 104 (1987) 897-903. [cited by applicant]
Yanagimoto et al., “A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.” Oncology Reports 24 (2010) 795-801. [cited by applicant]
Rammensee et al., “HLA ligandome tumor antigen discovery for personalized vaccine approach.” Expert Review of Vaccines 12 (2013) 1211-1217. [cited by applicant]
Yutani et al., “A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.” Oncology Reports 30 (2013) 1094-1100. [cited by applicant]
Great Britain Combined Search and Examination Report dated Dec. 15, 2015, issued in Application GB1504502.4. [cited by applicant]
Weinschenk et al., “Integrated functional genomics approach for the design of patient-individual antitumor vaccines”, Cancer Research, Oct. 15, 2002, pp. 5818-5827, vol. 62, No. 20. [cited by applicant]
International Search Report of International Patent Application No. PCT/EP2016/055817 dated Aug. 30, 2016. [cited by applicant]
Garg et al.; “Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.” The Journal of Clinical Endocrin… [cited by applicant]
Yokoyama et al.; “Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells.” Clinical Cancer Research 14, No. 17 (2008): 5503-5511. [cited by applicant]
Fritsche et al.; “Pitfalls in HLA ligandomics—how to catch a li (e) gand.” Molecular & Cellular Proteomics 20 (2021). [cited by applicant]
Kivelä-Rajamäki et al; “Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid.” Journal of periodontal research 38, No. 6 (2003): 583-590. (abstract). [cited by applicant]
Arafat et al.; “Tumor-specific expression and alternative splicing of the col. 6A3 gene in pancreatic cancer.” Surgery 150, No. 2 (2011): 306-315. [cited by applicant]
Nakagawa, Y et al.; “Arabidopsis plasma membrane protein crucial for Ca2+ influx and touch sensing in roots.” Proceedings of the National Academy of Sciences 104, No. 9 (2007): 3639-3644. [cited by applicant]
Udaka et al.; “An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries.” Immunogenetics 51 (2000): 816-828. (Abstract). [cited by applicant]
Ljunggren et al.; “Empty MHC class I molecules come out in the cold.” Nature 346, No. 6283 (1990): 476-480. (Abstract). [cited by applicant]
Hervé et al.; “On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules.” Molecular immunology 34, No. 2 (1997): 157-163. [cited by applicant]
Tsang et al.; “Antigen presentation by mouse CD4+ T cells involving acquired MHC class II: peptide complexes: another mechanism to limit clonal expansion ?. ” Blood, The Journal of the American Society of Hematology 101… [cited by applicant]